公开(公告)号：EP1689493A1

公开(公告)日：2006-08-16

申请号：EP03819270.4

申请日：2003-12-05

申请人： Bristol-Myers Squibb Pharma Company

发明人： DEGNAN, Andrew, P. ,  CHEN, Ling ,  CIVIELLO, Rita ,  DUBOWCHIK, Gene, M. ,  HAN, Xiaojun ,  JIANG, Xiang, Jun, J. ,  MACOR, John, E. ,  TORA, George ,  LUO, Guanglin

IPC分类号： A61P25/06 ,  A61K31/535 ,  A61K31/52 ,  A61K31/55 ,  A61K31/54 ,  A61K31/495 ,  A61K31/50 ,  C07D239/00 ,  C07D243/10 ,  C07D265/00 ,  C07D285/00

CPC分类号： C07D471/04 ,  C07D209/08 ,  C07D231/56 ,  C07D249/18 ,  C07D401/06 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  C07D471/10 ,  C07D491/10

摘要： The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.